Evaxion A/S
EVAX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001828253
No open-market purchases or sales by Evaxion A/S insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $4.93M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Evaxion A/S as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 6
- −3 vs. Q4 2023
- Shares held
- 381.0K
- −66.1K (−14.8%) vs. Q4 2023
- Total value
- $1.22M
- +$905.1K (+288.1%) vs. Q4 2023
- New holders
- 2
- 0 more added
- Sold out
- 5
- 4 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EVAX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $4.93M |
| Q1 2026 | 17 | $5.74M |
| Q4 2025 | 15 | $6.81M |
| Q3 2025 | 8 | $5.00M |
| Q2 2025 | 9 | $3.27M |
| Q1 2025 | 10 | $2.50M |
| Q4 2024 | 10 | $681.8K |
| Q3 2024 | 8 | $1.71M |
| Q2 2024 | 6 | $1.31M |
| Q1 2024 | 6 | $1.22M |
| Q4 2023 | 9 | $314.2K |
| Q3 2023 | 10 | $115.9K |
| Q2 2023 | 9 | $209.8K |
| Q1 2023 | 9 | $291.4K |
| Q4 2022 | 8 | $166.9K |
| Q3 2022 | 6 | $377.0K |
| Q2 2022 | 9 | $442.0K |
| Q1 2022 | 12 | $2.06M |
| Q4 2021 | 12 | $4.76M |
| Q3 2021 | 7 | $3.28M |
| Q2 2021 | 7 | $3.33M |
| Q1 2021 | 10 | $5.12M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Evaxion A/S; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 367,000 | $1.17M | 0.03% | +367,000 | New |
| Citadel Advisors LLC | 8,141 | $26.1K | 0.00% | −16,489−66.9% | Reduced |
| Beacon Capital Management, LLC | 4,863 | $15.6K | 0.00% | −43,770−90.0% | Reduced |
| JPMorgan Chase & Co | 705 | $2.26K | 0.00% | −8,292−92.2% | Reduced |
| Rhumbline Advisers | 290 | $928 | 0.00% | −2,619−90.0% | Reduced |
| Tower Research Capital LLC (TRC) | 30 | $96 | 0.00% | +30 | New |
| LM Advisors LLC | 0 | $0 | 0.00% | −337,336−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −14,000−100.0% | Sold out |
| Moloney Securities Asset Management, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −386−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −277−100.0% | Sold out |